The DF/HCC Program in Biostatistics and Computational Biology fosters a broad range of research into statistical, computational and mathematical questions that arise in cancer investigations. Its members are engaged in trans-disciplinary and inter-programmatic projects across population, clinical and basic cancer research. Biostatistics has been a Program since the formation of DF/HCC and was rated as outstanding at the time ofthe last CCSG renewal. The name ofthe Program was changed to Biostatistics and Computational Biology in 2010, with the support ofthe EAB, in order to recognize the strong contribution of computational biologists. This Program is led by G. Parmigiani and R. Betensky and has 45 members from all member institutions. Members are affiliated with two departments at HSPH (Biostatistics and Epidemiology) and six departments at HMS (Biological Chemistry and Molecular Pharmacology, Population Medicine, Medicine, Health Care Policy, Pediatrics and Radiation Oncology). The Program has two Specific Aims: 1) to develop and disseminate new tools in statistical science and computational biology that respond to emerging areas of cancer research;and 2) to develop software for the implementation of these tools. The Biostatistics and Computational Biology Program continues to be highly successful in securing external funding. In 2009, peer-reviewed grant funding attributed to the Program was $14.4 million in total costs, of which nearly $7 million was from NCI (49%) and $7.4 million was from other peer-reviewed sponsors. Attesting to the productivity and interactivity ofthe Program are the 1,666 publications authored by members during the project period, of which 4.2% were intra-programmatic, 44% were inter-programmatic and 33% were inter-institutional collaborations.
The DF/HCC Program in Biostatistics and Computational Biology fosters research into the mathematical, computational, and statistical questions that arise in cancer research. It supports methodological as well as inter-disciplinary and inter-programmatic research across population, clinical and basic cancer research.
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233|
|Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252|
|Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62|
|Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303|
|Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296|
|Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:|
|Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991|
|Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187|
|Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950|
Showing the most recent 10 out of 411 publications